Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon” or the “Company”) today announced that its stockholders have approved Proposa...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences&rs...
Ocutrx Technologies, a global technology company developing revolutionary medical devices with augmented reality (AR), extended reality (XR) and artificial...
“WeightWatchers is at a pivotal point where we can build new capabilities that expand our market, reinforced by our foundational strengths,” sa...
As previously announced on March 24, 2023, Sanofi commenced a cash tender offer to purchase all outstanding shares of common stock of Provention Bio, Inc. ...
While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the name Ayala Pharmaceuticals. The merged compa...
“We are excited to complete LG Chem’s acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world’...
"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,...
The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by advancing its leadership in specialty services and global platform of ph...
Sesen Bio Stockholders Expected to Receive Approximately $70 Million Special Cash Dividend, an Increase from up to $25 Million Previously Announced Cont...
© 2025 Biopharma Boardroom. All Rights Reserved.
